The effect of inhaled corticosteroids on hypothalamic-pituitary-adrenal axis

Indian Journal of Pharmacology

Volumn 44, Issue 3, 2012, Pages 314-318

  Moghaddam, Keivan Gohari ^a   Rashidi, Negin ^a   Meybodi, Hamidreza Aghaei ^a   Rezaie, Nader ^a   Montazeri, Mahdi ^a   Heshmat, Ramin ^a   Annabestani, Zohreh ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adrenal cortex function tests; adrenal insufficiency; asthma; beclomethasone dipropionate; fluticasone

Indexed keywords

BECLOMETASONE DIPROPIONATE; FLUTICASONE PROPIONATE; GLUCOSE; HYDROCORTISONE; TETRACOSACTIDE;

ADRENAL FUNCTION; ADULT; ARTICLE; ASTHMA; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HOARSENESS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THRUSH;

EID: 84861915350     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.96300     Document Type: Article

References (25)

1. The Global Initiative For Asthma: GINA At-A-Glance Asthma Management Reference. Updated 2010. Available from: http://www.ginasthma.com/ GuidelinesResources.asp?l1=2 and l2=0. [Last Accessed on 2011 Feb 25].
2. Belda J, Margarit G, Martinez C, Bellido-Casado J, Casan P, Torrejon M, et al. Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in asthma exacerbations Eur Respir J 2007;30:1143-9.
3. Casale TB, Nelson HS, Stricker WE, Raff H, Newman KB. Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients. Ann Allergy Asthma Immunol 2001;87:379-85.
4. Cooper MS, Stewart PM. Corticosteroid Insufficiency in Acutely Ill Patients. N Engl J Med 2003;348:727-34.
5. Meibohm B, Hochhaus G, Rohatagi S, Mollman H, Barth J, Wagner M, et al. Dependency of cortisol suppression on the administration time of inhaled corticosteroids. J Clin Pharmacol 1997;37:704-10.
6. Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 1997;52:476-82.
7. Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006;28:1042-50.
8. Wallace I, Cunningham S, Lindsay J. The diagnosis and investigation of adrenal insufficiency in adults. Ann Clin Biochem 2009;46:351-67.
9. Barnes NC, Marone G, Di Maria GU, Visser S, Ultama I, Payne SL. A comparison of fluticasone propionate 1 mg daily with beclomethasone dipropionate 2 mg daily in the treatment of severe asthma. Eur Respir J 1993;6:877-85.
10. Donnelly R, Williams KM, Baker AB. Effects of Budesonide and Fluticasone on 24-Hour Plasma Cortisol. Am J Respir Crit Care Med 1997;156:1746-51.
11. Ayres JG, Bateman ED, Lundback B, Harris TA. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. Eur Respir J 1995;8:579-86.
12. Derendorf H, Hochhaus G, Meibohm B, Mollmann H, Barth J. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 1998;101: S440-6.
13. Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Doseresponse relation of inhaled fluticasone propionate in adolescents and adults with asthma: Metaanalysis. BMJ 2001;323:1-7.
14. Wilson AM, Sims EJ, Lipworth BJ. Dose response with fluticasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment. Clin Endocrinol (Oxf) 1999;50:329-35.
15. Szefler S, Rohatagi S, Williams J, Lioyd M, Kundu S, Banerji D. Ciclesonide, A novel inhaled steroid, does not affect hypothalamic-pituitary- adrenal axis function in patients with moderate-to-severe persistent asthma. Chest 2005;128:1104-14.
16. Kelly HW. Comparison of Inhaled Corticosteroids: An Update. Ann Pharmacother 2009;43:519-27.
17. National Heart Lung and blood Institute, 28 August2007: Expert Panel Report 3 (EPR3): Guidelines for the Diagnosis and Management of Asthma. Available from: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm. [Last Accessed on 2010 Dec 10].
18. Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insufficiency. Ann Intern Med 2003;139:194-204.
19. Pauwels RA, Yernault JC, Demedts MG, Geusens P. Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Am J Respir Crit Care Med 1998;157:827-32.
20. Fitzgerald D, Asperen PV, Mellis C, Honner M, Smith L, Ambler G. Fluticasone propionate 750 μg/day versus beclomethasone dipropionate 1500 μg/day: Comparison of efficacy and adrenal function in paediatric asthma. Thorax 1998;53:656-61.
21. Brus R. Effects of high-dose inhaled corticosteroids on plasma cortisol concentrations in healthy adults. Arch Intern Med 1999;159:1903-8.
22. Fardon TC, Lee DK, Haggart K, McFarlane LC, Lipworth BJ. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med 2004;170:960-6.
23. Brown PH, Blundell G, Greening AP, Crompton GK. Do large volume spacer devices reduce the systemic effects of high dose inhaled corticosteroids? Thorax 1990;95:736-9.
24. Hagg E, Asplund K, Lithner F. Value of basal plasma cortisol assays in the assessment of pituitary -adrenal insufficiency. Clin Endocrinol (Oxf) 1987;26:221-6.
25. Adams NP, Lasserson TJ, Cates CJ, Jones PW. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev 2007: CD002310.